SoftServe Acquires Hoverstate
7.6.2023 16:01:00 EEST | Business Wire | Press release
SoftServe, a global IT consulting firm, today announced its acquisition of Hoverstate, a full-service digital agency specializing in mobile and web-based solutions. The acquisition positions both companies as a single software solution source for digital native organizations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230607005221/en/
SoftServe, a global IT consulting firm, has announced acquiring Hoverstate, a full-service digital agency specializing in mobile and web-based solutions. (Graphic: Business Wire)
SoftServe’s dynamic offerings and global footprint enhance Hoverstate’s intelligent process automation expertise and its key partnership with the Pega Platform from Pegasystems, the low-code platform provider empowering the world’s leading enterprises to Build for Change®. Clients now have deeper access to accelerated cloud-based digital processes and increased developmental efficiencies using data and analytics, AI/ML, and experience-based software engineering.
“As a SoftServe company, Hoverstate expands our suite of innovative services to help our clients streamline processes and minimize costs in today’s macroeconomic environment,” said Chris Baker, SoftServe CEO. “Hoverstate takes a human-centric approach that results in amazing user experiences and robust business outcomes that will be amplified across SoftServe’s clients and prospects.”
Hoverstate is already known for helping companies improve customer service, deepen engagement, and reduce operating costs by up to 50% across industries. The acquisition reinforces and extends SoftServe’s industry expertise in the healthcare, life science, banking, financial services, transportation, and logistics sectors. It also further amplifies Hoverstate’s status as a Specialized Pega Partner for the platform’s solutions to a global client marketplace.
Hoverstate’s expertise with the Pega Platform accelerates the cost optimization associated with back-office process transformation. Their reputational design-driven approach to the front-end ensures deeper customer engagement. Further, Hoverstate brings marquee healthcare organizations to SoftServe's client list. These organizations will accelerate business outcomes by leveraging their existing investments in technology solutions provided by Amazon Web Services, Google, Microsoft, NVIDIA, and SiteCore. Hoverstate’s holistic methodology enhanced by SoftServe’s AI/ML and advisory capabilities will create profound business outcomes for clients.
SoftServe has more than 12,000 associates spanning 14 countries in North America, EMEA, APAC, and Latin America. Along with Hoverstate’s footprint in offices across the U.S. and Italy, Hoverstate Chief Strategy Officer and Managing Partner Rob Fauver will accompany Chief Innovation Officer and Managing Partner Kyung Ahn as part of the SoftServe family.
“We believe joining a strong digital transformation services provider is the best path to deliver increased capabilities and exceptional digital solutions to our clients,” Fauver said. “SoftServe shares our people-first values. The cultural synergies between the firms are unmatched. SoftServe’s global delivery network gets us closer to our clients. It makes our support agile and scalable. We’re ready for the future.”
To learn more about SoftServe acquiring Hoverstate, please visit this webpage.
ABOUT SOFTSERVE
SoftServe is a leading IT consulting company transforming and optimizing how enterprises and software companies do business. Our end-to-end approach assures innovation, quality, and speed across the healthcare, retail, energy, manufacturing, and financial services verticals.
Visit our website, blog, LinkedIn, Facebook, and Twitter pages.
ABOUT HOVERSTATE
Hoverstate is a full-service digital agency focusing on digital strategy, mobile apps, web development and business applications with a deep expertise in the health insurance, pharmaceutical, and life sciences industries. The main capabilities are: AppDev, Service Design/CX/UX, UI, DevOps & Infrastructure, Big Data, AI/ML, RPA, Consultancy across primarily Healthcare and Media, Education, Financial Services verticals.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230607005221/en/
Contact information
Kayla Cash
Public Relations Manager
SoftServe, Inc.
kcash@softserveinc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Caidya Names Michael Clay COO to Drive Operational Excellence and Advance Multi-Regional Clinical Development17.2.2026 16:10:00 EET | Press release
Caidya, a leading global, mid-sized CRO focused on accelerating clinical development for innovative biopharmaceutical companies, today announced the appointment of Michael Clay as chief operating officer (COO). Clay will lead Caidya’s global operational delivery, client engagement model, and execution strategy, further strengthening the company’s ability to serve innovative biopharma sponsors across the U.S., Europe, and Asia-Pacific. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260217431202/en/ Michael Clay, Caidya's Chief Operating Officer Clay brings a distinguished track record in global project delivery and site relationship strategy. He has led large-scale global programs across 60+ countries and built high-performing delivery organizations known for operational rigor and sponsor trust. Notably, Clay has extensive leadership experience across Asia-Pacific, where speed, regulatory nuance, and close site collaboration
Gurobi Appoints Dr. Pascal Van Hentenryck to Lead AI Innovation Lab17.2.2026 16:00:00 EET | Press release
Gurobi Optimization, LLC, the leader in decision intelligence technology, is pleased to announce that Dr. Pascal Van Hentenryck has joined the company as head of the Gurobi AI Innovation Lab (GAIL). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260217170385/en/ Dr. Pascal Van Hentenryck, Head of AI Innovation Lab, Gurobi Optimization As part of Gurobi’s long-term product and technology strategy, the Gurobi AI Innovation Lab is a focused Research & Development initiative dedicated to advancing the combination of multiple AI technologies with optimization to solve complex, large-scale, and time-critical decision problems. “Pascal brings exceptional leadership across mathematical optimization and complementary AI technologies,” said Dr. Oliver Bastert, CTO, Gurobi Optimization. “While mathematical optimization remains the best approach for most decision problems—as demonstrated by thousands of successful customer implementatio
Watchmaker Genomics Licenses CRISPR-Cas9 Intellectual Property from Caribou Biosciences to Increase Throughput and Reduce Sequencing Cost per Sample17.2.2026 15:00:00 EET | Press release
Watchmaker Genomics, an innovator in high-performance solutions for next-generation sequencing (NGS), today announced a non-exclusive license with Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, for certain foundational CRISPR-Cas9 intellectual property for use in NGS library preparation. While CRISPR-Cas9 technologies are most commonly associated with their unique ability to find and cut for genome editing, Watchmaker is leveraging it in a fundamentally different way: as a programmable, stoichiometric binding tool to address one of the most persistent and under-optimized steps in NGS workflows – library normalization. “Normalization has quietly become a bottleneck as sequencing throughput has scaled,” said Brian Kudlow, CSO and Founderat Watchmaker Genomics. “This license gives us the freedom to rethink normalization from first principles, using CRISPR-Cas9 in a way that’s orthogonal to editing but highly aligned with modern sequenc
Esri and Pix4D Launch Real-Time Terrestrial Mapping Workflow17.2.2026 15:00:00 EET | Press release
Esri, the global leader in geographic information system (GIS) technology, has launched a terrestrial mapping workflow with Pix4D. A Switzerland-based photogrammetry software company, Pix4D specializes in mobile reality capture and site-digitization. The combined workflow allows field teams to capture and process asset data and manage it within ArcGIS, Esri’s geospatial platform. Field teams use the PIX4Dcatch app with real-time kinematics (RTK) devices to scan trenches and infrastructure. The generated high precision georeferenced records can now be published into Esri’s ArcGIS Online. Scans become 3D models and point clouds, viewable as a Scene Layer. Existing data can also be visualized in augmented reality for instant “as-designed” versus “as-built” verification before closing trenches. “We are focused on turning hidden infrastructure into functional data,” said Andrey Kleymenov, CEO of Pix4D. “By connecting PIX4Dcatch with a compatible RTK device to the Esri ecosystem, we are enab
Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression17.2.2026 13:30:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the successful achievement of the primary endpoint in the ongoing Phase 3 COMP006 trial, the second of two Phase 3 trials, which is evaluating two fixed doses of COMP360, a synthetic, proprietary formulation of psilocybin, for treatment-resistant depression (TRD). The primary endpoint was the difference in change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) scores between the 25 mg and 1 mg groups at Week 6. Two fixed doses – administered 3 weeks apart – of COMP360 25 mg versus 1 mg demonstrated a highly statistically significant reduction in symptom severity with a p-value of <0.001 and a clinically meaningful difference of -3.8 points in change at the primary endpoint. Across COMP005 and COMP006 to date, COMP360 is demonstrating a generally well-tolerated and safe profile, with treatment-emergent adverse events (
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom